Johnson & Johnson (NYSE:JNJ) Shares Acquired by First National Bank Sioux Falls

Posted by Defense World Staff on Jul 5th, 2023

First National Bank Sioux Falls boosted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,222 shares of the company’s stock after purchasing an additional 111 shares during the quarter. First National Bank Sioux Falls’ holdings in Johnson & Johnson were worth $809,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in JNJ. Veracity Capital LLC grew its stake in Johnson & Johnson by 1.2% during the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock valued at $888,000 after acquiring an additional 59 shares in the last quarter. LCM Capital Management Inc increased its stake in Johnson & Johnson by 0.7% in the 4th quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after buying an additional 61 shares during the period. Arbor Investment Advisors LLC lifted its position in Johnson & Johnson by 2.3% in the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock worth $476,000 after buying an additional 61 shares in the last quarter. Sierra Capital LLC boosted its stake in shares of Johnson & Johnson by 0.6% during the 4th quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after buying an additional 61 shares during the period. Finally, Retirement Planning Group grew its holdings in shares of Johnson & Johnson by 1.8% during the 4th quarter. Retirement Planning Group now owns 3,437 shares of the company’s stock valued at $607,000 after acquiring an additional 62 shares in the last quarter. 67.57% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent research reports. Atlantic Securities lowered their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 19th. TheStreet downgraded Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, May 19th. Raymond James reduced their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday, April 19th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. Finally, Morgan Stanley upped their price objective on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $171.57.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

JNJ opened at $163.35 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. The stock’s 50 day moving average price is $160.74 and its two-hundred day moving average price is $162.73. The firm has a market capitalization of $424.50 billion, a P/E ratio of 34.17, a price-to-earnings-growth ratio of 2.83 and a beta of 0.55. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04.

Johnson & Johnson (NYSE:JNJ – Free Report) last announced its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.51 by $0.17. The business had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. Johnson & Johnson’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the company posted $2.67 earnings per share. On average, equities analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd were paid a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 2.91%. The ex-dividend date was Monday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is presently 99.58%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.